Wall Street analyst estimates for Silo Pharma, Inc. (SILO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-12-02 | $-4.80 | ||
| 2026-08-13 | $-0.76 | $-0.32 | -137.5% |
| 2026-05-13 | $-1.80 | $-0.32 | -462.5% |
| 2026-03-27 | $-0.99 | ||
| 2025-11-13 | $-0.12 | $-0.20 | +40.0% |
| 2025-08-13 | $-0.19 | $-0.20 | +5.0% |
| 2025-05-09 | $-3.45 | $-0.21 | -1542.9% |
| 2025-03-28 | $-0.41 | $-0.20 | -105.0% |
Valuation Ratios
| Price / Book | 0.39 |
| EV / EBITDA | 0.12 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -$669480 | $847407 | 0 | $40569 | 0 | $71264 | $72102 | $72102 | $72102 | $72102 |
| Cost of Revenue | 0 | 0 | $17550 | $27387 | 0 | $5004 | $5838 | $5838 | $5838 | $886057 |
| Gross Profit | -$669480 | $847407 | -$17550 | $13182 | 0 | $66260 | $66264 | $66264 | $66264 | -$813955 |
| Research & Development | 0 | 0 | 0 | $63465 | $26250 | $693910 | $1.3M | $845092 | $2.4M | $2.2M |
| Selling, General & Admin | $300994 | $313371 | $459830 | $864180 | $2.2M | $2.3M | $2.4M | $3.1M | $2.4M | $2.1M |
| Operating Expenses | $443494 | $490871 | $459830 | $943585 | $2.2M | $2.8M | $3.7M | $3.9M | $4.8M | $3.5M |
| Operating Income | -$393658 | -$470388 | -$594242 | -$930403 | -$2.2M | -$2.7M | -$3.6M | -$3.9M | -$4.7M | -$4.3M |
| EBITDA | 0 | $356536 | -$951914 | -$950366 | -$2.4M | $4.2M | -$3.9M | -$3.6M | -$4.4M | -$4.2M |
| Interest Expense | 0 | 0 | 0 | $62928 | $269267 | $3036 | $2199 | $4869 | $5084 | $37302 |
| Pre-tax Income | -$1.1M | $356536 | -$969463 | -$1.0M | -$2.7M | $4.2M | -$3.9M | -$3.6M | -$4.4M | -$4.2M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | $24876 | 0 | 0 | 0 | 0 |
| Net Income | -$1.1M | $356536 | -$969463 | -$1.0M | -$3.0M | $3.9M | -$3.9M | -$3.7M | -$4.4M | -$4.2M |
| EPS | $-16.65 | $7.50 | $-14.85 | $-18.60 | $-35.25 | $19.80 | $-25.65 | $-18.00 | $-17.85 | $-7.50 |
| EPS (Diluted) | $-16.65 | $7.50 | $-14.85 | $-18.60 | $-35.25 | $19.50 | $-25.65 | $-18.00 | $-17.85 | $-7.50 |
| Shares Outstanding (Diluted) | $66928 | $69443 | $65469 | $56153 | $87940 | $127896 | $152283 | $205325 | $245359 | $558818 |
Price
| Price | $1.76 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BDRX · CANF · CMND · CNSP · GRI · INM · JAGX
Explore sector: Healthcare · Biotechnology
More sections of SILO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks